MeiraGTx reports positive phase 2 results for AAV-GAD in Parkinson's disease, with 18-point motor function improvement and no serious adverse events.
MeiraGTx Holdings has reported positive results from its clinical study of AAV-GAD for Parkinson's disease, involving 14 participants. The treatment was safe, with no serious adverse events, and the high-dose group showed an 18-point improvement in motor function after 26 weeks. Both dosage groups also reported better quality of life. Following the news, MGTX stock rose by 13.2%. The company is now planning a phase 3 trial.
October 15, 2024
9 Articles